SOURCE-LINKED INTELLIGENCE

TrialAtlas: Multi-Agent Research Organization for Clinical Trial Design and Optimization

arXiv · AI, language, vision and robotics · article · Sep 18, 2026 · UTC

Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely on clinical development planning (CDP) and probability of technical and regulatory success assessment to anticipate development risks, yet these decisions remain labor-intensive and subjective, requiring experts across clinical science, statistics, regulatory affairs, and competitive intelligence to jointly acquire, synthesize, and reason over heterogeneous evidence. Here, we introduce TrialAtlas, a memory-augmented multi-agent research organizat

Read original source ↗ Open in workspace

recordType

paper

region

Global